Amy Case, MD
Pulmonary Disease · Austell, GANPI 1467664466
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $29,140 of the $40,398 with a category attached, or 72.1%. Boehringer Ingelheim accounts for 75.9% of it on its own, with 21 other manufacturers making up the rest. Reporting peaked in 2019 at $19,840 and has fallen 78.1% since, to $4,336 in 2025. Among pulmonary disease clinicians in GA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 94 payments — averaging $429.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$31K
- Genentech USA, Inc.$9K
- GSK$251
- Actelion Pharmaceuticals US, Inc.$159
- Insmed, Inc.$74
- Mallinckrodt Enterprises LLC$68
- plus $362 from 16 others
Across 303 payments — averaging $4826.93 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- United Therapeutics Corporation$514K
- Boehringer Ingelheim$443K
- Regeneron$149K
- Roche Products Limited$139K
- Kadmon Corporation LLC$108K
- Genentech, Inc.$40K
- plus $68K from 5 others
What the payments were for
- Consulting fees$7,40018%
- Speaking & faculty fees$29,14072%
- Travel & lodging$1,6344%
- Food & beverage$2,1975%
- Education$280%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 44 | $30,652 |
| Genentech USA, Inc. | 11 | $8,832 |
| GSK | 10 | $251 |
| Actelion Pharmaceuticals US, Inc. | 2 | $159 |
| Insmed, Inc. | 3 | $74 |
| Mallinckrodt Enterprises LLC | 3 | $68 |
| AstraZeneca | 2 | $43 |
| Optinose US, Inc. | 2 | $34 |
| Mylan Specialty L.p. | 1 | $32 |
| Resmed Corp | 2 | $31 |
| Pfizer | 2 | $31 |
| Jazz Pharmaceuticals Inc. | 2 | $28 |
| Tactile Systems Technology Inc | 1 | $26 |
| Pulmonx Corporation | 1 | $24 |
| Johnson & Johnson | 1 | $17 |
| Mallinckrodt Hospital Products Inc. | 1 | $17 |
| United Therapeutics Corporation | 1 | $16 |
| Amgen | 1 | $16 |
| Electromed, Inc. | 1 | $16 |
| Fisher & Paykel Healthcare Inc | 1 | $15 |
| Grifols USA, LLC | 1 | $14 |
| Inogen, Inc. | 1 | $2 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OFEV$17,425
- Esbriet$8,369
- TRELEGY ELLIPTA$114
- OPSUMIT$110
- UPTRAVI$110
How this compares
$40,398 in reported general payments places this provider in the 90th percentile of 365 pulmonary disease providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 117 | $1,465,366 |
| Pirfenidone | 33 | $130,093 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 63 | $51,405 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 31 | $17,318 |
| Breo ElliptaFluticasone/Vilanterol | 33 | $16,907 |
| SymbicortBudesonide/Formoterol Fumarate | 21 | $5,548 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 13 | $2,189 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 30 | $1,340 |
| Ventolin HfaAlbuterol Sulfate | 19 | $989 |
| Prednisone | 88 | $512 |
| Esomeprazole Magnesium | 15 | $337 |
| Azithromycin | 16 | $323 |
| Omeprazole | 17 | $321 |
| Montelukast Sodium | 18 | $190 |
| Fluticasone Propionate | 18 | $176 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev | $30,652 | $1,465,366117 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $251 | $85,630127 claims |
| AstraZenecaSymbicort | $43 | $5,54821 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 365 pulmonary disease providers in Georgia.
Other pulmonary disease in Austell
- Chad MillerAustell$382K
- Steven HarrisAustell$35K
- Lawrence McDermottSavannah$963K
- Vivek SambharaGainesville$417K
- Nehal BhattAthens$371K
- Maria MascoloRincon$358K
- Colin SwensonAtlanta$255K
- David MillerDecatur$206K
- Michael MullinsSavannah$132K
- Hitendra PatelMarietta$104K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.